Beximco Pharmagdr Regs Stock Fundamentals
| R2WA Stock | EUR 0.41 0.00 0.00% |
BEXIMCO PHARMAGDR REGS fundamentals help investors to digest information that contributes to BEXIMCO PHARMAGDR's financial success or failures. It also enables traders to predict the movement of BEXIMCO Stock. The fundamental analysis module provides a way to measure BEXIMCO PHARMAGDR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BEXIMCO PHARMAGDR stock.
BEXIMCO |
BEXIMCO PHARMAGDR REGS Company Return On Equity Analysis
BEXIMCO PHARMAGDR's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current BEXIMCO PHARMAGDR Return On Equity | 0.12 |
Most of BEXIMCO PHARMAGDR's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BEXIMCO PHARMAGDR REGS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, BEXIMCO PHARMAGDR REGS has a Return On Equity of 0.1163. This is 100.49% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The return on equity for all Germany stocks is 137.52% lower than that of the firm.
BEXIMCO PHARMAGDR REGS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BEXIMCO PHARMAGDR's current stock value. Our valuation model uses many indicators to compare BEXIMCO PHARMAGDR value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BEXIMCO PHARMAGDR competition to find correlations between indicators driving BEXIMCO PHARMAGDR's intrinsic value. More Info.BEXIMCO PHARMAGDR REGS is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers reporting about 0.57 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for BEXIMCO PHARMAGDR REGS is roughly 1.76 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BEXIMCO PHARMAGDR's earnings, one of the primary drivers of an investment's value.BEXIMCO Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BEXIMCO PHARMAGDR's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BEXIMCO PHARMAGDR could also be used in its relative valuation, which is a method of valuing BEXIMCO PHARMAGDR by comparing valuation metrics of similar companies.BEXIMCO PHARMAGDR is rated fifth in return on equity category among its peers.
BEXIMCO Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.14 % | |||
| Shares Outstanding | 446.11 M | |||
| Shares Owned By Institutions | 2.09 % | |||
| Gross Profit | 15.71 B | |||
| Debt To Equity | 27.50 % | |||
| Current Ratio | 2.26 X | |||
| Earnings Per Share | 0.10 X | |||
| Number Of Employees | 5.5 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 563.15 M | |||
| Annual Yield | 0.06 % |
About BEXIMCO PHARMAGDR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BEXIMCO PHARMAGDR REGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BEXIMCO PHARMAGDR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BEXIMCO PHARMAGDR REGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. Beximco Pharmaceuticals Limited was founded in 1976 and is headquartered in Dhaka, Bangladesh. Beximco Pharmaceuticals operates under Drug Manufacturers - Major classification in Germany and traded on Frankfurt Stock Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in BEXIMCO Stock
BEXIMCO PHARMAGDR financial ratios help investors to determine whether BEXIMCO Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BEXIMCO with respect to the benefits of owning BEXIMCO PHARMAGDR security.